Pfizer Reaffirms 2026 Guidance Amid CFO Transition
Pfizer Inc. confirmed on 18 June 2026 that its 2026 financial outlook remains unchanged. The company reiterated a full‑year revenue projection of $59.5 billion to $62.5 billion and an adjusted diluted earnings‑per‑share range of $2.80 to $3.00. This guidance was originally issued on 16 December 2025 and was restated during the first‑quarter earnings call held on 5 May 2026.
Chief Financial Officer Dave Denton announced he will leave Pfizer effective 15 August 2026 to assume a role in the consumer‑goods sector. Cecile Guegan, currently senior vice‑president for finance in Pfizer’s global biopharmaceutical business, will serve as interim CFO beginning 16 August 2026. Pfizer indicated it will conduct a search for a permanent CFO, considering both internal and external candidates.